ASX-listed Mesoblast climbs on Ryoncil pricing information release

Shares of ASX-listed Mesoblast MSB.AX rise 2.88% to A$2.14, set for third session of consecutive gains — if trends hold

Stock among the biggest percentage gainers in the ASX200 index .AXJO

Biotech releases pricing information for its product Ryoncil, used to treat a serious condition called graft-versus-host disease, which can happen after a person gets a blood cell transplant

Treatment centres can now order kits tailored to the appropriate dosage for each patient, with pricing applied uniformly, regardless of patient weight — MSB

Pricing details for Ryoncil are now available in all four major drug pricing compendia in the United States

Says that this follows approval and publication by the U.S. Food and Drug Administration of the revised Ryoncil label, which includes revisions to the product prescribing information

Stock down 31.3% YTD including current session